

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board
SBI Holdings, Inc.
Yoshitaka Kitao
Chief Executive Officer

Japan, 22 June 2012

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Kenji Hirai, Mr Tomoya Asakura, Mr Takashi Okita, Mr Noriaki Maruyama, Mr Shumpei Morita, Mr Shinji Yamauchi, Mr Makoto Miyazaki, Mr Yoshimi Takahashi, and Mr Masaki Takayanagi, the non-executive Directors are Mr Yasutaro Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura and Mr Hiroshi Tasaka and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Takeshi Natsuno and Mr Akihiro Tamaki.

June 22, 2012

SBI Holdings, Inc.

(TOKYO: 8473 / Hong Kong: 6488)

**Notice on Investments in Chinese Bioventure Yian Biotech,
and Establishment of Joint Venture**

The SBI Group hereby announces that it will acquire 40% of the outstanding equity interests in the Chinese bioventure Suzhou Yian Biotech Co., Ltd. (head office: Suzhou, China; Chairman: Jiang Zhenxiong; “Yian Biotech”). In addition, the Group and the current owners of Yian Biotech have agreed to establish a joint venture (“the new joint venture”) in China, engaged in selling products that Yian Biotech will manufacture, including an active ingredient of 5-ALA as well as medicines, health foods and cosmetics that contain 5-ALA.

Yian Biotech will begin to produce the 5-ALA active ingredient as well as medicines, health foods and cosmetics that contain 5-ALA with cooperation from the SBI Group, which will provide Yian Biotech with technologies needed to manufacture various products and information necessary to obtain the related approval and licenses in China. The new joint venture will have exclusive sales rights to all the products to be manufactured by Yian Biotech. In addition, the SBI Group is to acquire 60% of the outstanding equity interests of the new joint venture. Furthermore, the new joint venture will import 5-ALA-contained products manufactured by SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative: Yoshitaka Kitao), a member of the SBI Group, and sell them in China.

The SBI Group, together with its partners in Japan and abroad, is currently developing medicines, health foods and cosmetics that use 5-ALA, and establishing a logistics system for these products. We will actively expand the 5-ALA related businesses overseas, hoping to contribute to the health of as many people as possible in the world.

Outline of Yian Biotech

- Corporate name: Suzhou Yian Biotech Co., Ltd.
- Head office: 50 Weixin Road, Suzhou Industrial Park, Suzhou China
- Establishment: December 2006
- Capital: RMB 60 million
- Chairman: Jiang Zhenxiong
- Business (plan):
 1. Manufacture of an active ingredient of 5-ALA
 2. Production of medicines, health foods and cosmetics that contain 5-ALA

* The above-mentioned scheme assumes that approval and licenses from the related Chinese authorities are obtained.

For further information, please contact:

SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126